Navigation Links
Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives
Date:5/28/2008

ly great science and great medicine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon(R) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax(TM) (raxibacumab) is in late-stage development for the treatment of inhalation anthrax, and the Company is on track to begin the delivery in fall 2008 of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. Other HGS drugs in clinical development include two TRAIL receptor antibodies for the treatment of cancer. The initiation of dosing is imminent in a Phase 1 trial of HGS1029, a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins, in patients with advanced solid tumors. In addition, HGS has substantial financial rights to three products in the GlaxoSmithKline clinical development pipeline.

For more information about HGS, please visit the Company's web site at http://www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

SAFE HARBOR STATEMENT

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent,
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
2. St. Jude Finds Dancing Hair Cells Are Key to Humans Acute Hearing
3. Increases in West Nile Virus Replikin Concentrations Precede Increases in the Number of Human Cases
4. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
5. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
6. First Human Implant of New Archus Orthopedics Facet Replacement System
7. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
8. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
9. Data Show SuperGens MP-470 is Safe in Humans
10. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
11. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...Nov. 19 Riverain Medical announced...ading Canadian medical imaging distributor Christi...nd OnGuard Chest Xray CAD. The exclusive agreement...products to the Canadian market through Christie G..., SoftView Enhanced Chest Imaging increases the ...
(Date:11/19/2009)...Mass., Nov. 19 Ligon Discovery, In...ay technology to find drugs against high-value tar...ed financing led by incTANK Ventures. The company ...very campaign that will screen over 100 high-value...cTANK Ventures General Partner Christian Bailey jo...
(Date:11/19/2009)...nternational Internet Week of Action ,, SILVER...he U.S. Food and Drug Administration today complet...called the International Internet Week of Action (...medical products. ,, (Logo: http://www.newscom...the effort, the FDA,s Office of Criminal Investiga...
Breaking Medicine Technology:Riverain Medical Partners With The Christie Group In Canada To Offer SoftView Enhanced Chest Imaging and OnGuard Chest X-Ray CAD Technologies 2Cambridge-based Ligon Discovery Raises $1M in Seed Funding 2Cambridge-based Ligon Discovery Raises $1M in Seed Funding 3UPDATE: FDA Issues 22 Warning Letters to Web site Operators 211 More Children Die From Swine Flu 3A CDC 59676 111 More Children Die From Swine Flu 3A CDC 59676 211 More Children Die From Swine Flu 3A CDC 59676 3Chicago Veterinary Emergency Services Goes 24 7 for Emergency Care 59672 1Chicago Veterinary Emergency Services Goes 24 7 for Emergency Care 59672 2News In Red and Blue 3A How Messages About Social Factors and Health Can Backfire 59668 1News In Red and Blue 3A How Messages About Social Factors and Health Can Backfire 59668 2News In Red and Blue 3A How Messages About Social Factors and Health Can Backfire 59668 3
...eets Primary and All Secondary Endpoints, San Car...SX ), a biopharmaceutical company focused on devel...nced positive top-line results from,its second piv... containing,the TRPV1 agonist -- synthetic capsaic...). The study, a multi-center, double-blind, contro...
...) Stent shows no additional very late stent thromb...,Boston Scientific Corporation (NYSE: BSX ) today...XUS II clinical trial, demonstrating continued,lon...axel-eluting stent,system. Among the findings, the... between years four and five, while the bare-metal...
Other Medicine Technology:NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 2NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 3NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 4NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 5NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 6NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 7Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent 2Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent 3Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent 4
(Date:11/20/2009)...ass., Nov. 20 Following a recall b... removed from sale Shedd,s Country Crock ® Si... Country Crock ® Side Dishes DELUXE Four Chee..., The following code dates and UPCs are affecte... DELUXE Cheddar Broccoli Rice 21 oz, UPC 027400218...
(Date:11/20/2009)...IFA, Israel, November 20 ...http://www.CVSLMEDICAL.COM , a leading,developer o...y announced that,the company,s Board of Directors ...ope, Canada and the Far East for its proprietary n...r all angioplasty (PCTA) procedures. , Ca...
(Date:11/20/2009)...exposure to formaldehyde used for embalming in the...d risk of death from myeloid leukemia, according t... Journal of the National Cancer Institute . , Pr...mphohematopoietic malignancies and brain cancer in...rkers, all of whom may have worked with formaldehy...
(Date:11/20/2009)... one-third buying 90-day supply, study finds , ...g a three-month supply of prescription drugs is up...ly, according to a new study. , U.S. researcher...gs between 2000 and 2005, and found that patients ...onth supply saved an average 29 percent in out-of-...
(Date:11/20/2009)...LD, Mo., Nov. 20 Missouri state em...i regions will now have the option to choose Mercy...ay between Missouri Consolidated Health Care Plan ...t and South Central Missouri regions include the f..., Dade, Dallas, Douglas, Greene, Hickory, Howell, ...
Breaking Medicine News(10 mins):Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2Health News:Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East 2Health News:Funeral industry workers exposed to formaldehyde face higher risk of leukemia 2Health News:Three-Month Supply Lowers Drug Costs 2Health News:Missouri Consolidated Health Care Plan Provides Mercy Health Plans Option 2
...on activates when a friend,s voice calls, scientis...Scientists say they,ve spotted a brain region that...e sound of a familiar voice calling a person,s nam...ed to detect brain activity associated with a give...
...hough arterial vascular disease is widespread and ...oo often fail to spot and treat it, according to a...e Columbia University Medical Center and Weill Cor... almost exclusively on males, so in many cases we ...
...hird Quarter Revenues Increase 89% to $3.51 Millio... Q3 of 2006, -- Third Quarter Net Income Before Ta... versus $0.74 Million for Q3 of 2006, NEW YORK...try engaged in the development, manufacture and,di...
...NTA, Nov. 21 Eclipsys Corporation(R),(Nasdaq: EC...will be,participating in the Merrill Lynch Health ...k in New York, NY., (Logo: http://www.newscom.co...rested parties are invited to,listen to the presen...
...UTZ SHAMIR, Israel, Nov. 21 Shamir,Optical Indust...ue its third,quarter 2007 earnings results on Tues...ence call to discuss the results at 9:00 A.M. EST ...five minutes before,the conference call is schedul...
...utives typically ignore data on plans that give be...21 (HealthDay News) -- Many large American compani...improve the quality and value of their workers, h...hers surveyed 609 executives of the largest emplo...
Other Medicine News:Health News:Arterial vascular disease underdiagnosed, undertreated in older US women 2Health News:Arterial vascular disease underdiagnosed, undertreated in older US women 3Health News:Arterial vascular disease underdiagnosed, undertreated in older US women 4Health News:China Yingxia International Announces 2007 Third Quarter Financial Results Conference Call 2Health News:China Yingxia International Announces 2007 Third Quarter Financial Results Conference Call 3Health News:China Yingxia International Announces 2007 Third Quarter Financial Results Conference Call 4Health News:China Yingxia International Announces 2007 Third Quarter Financial Results Conference Call 5Health News:Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 2Health News:Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 3Health News:Shamir Optical Industry Ltd. to Host Conference Call Announcing Third Quarter 2007 Earnings Results 2Health News:Most U.S. Companies Do Little to Boost Worker Health Benefits 2
...dvance in digital diagnostic ultrasound for the op...s and receives noise-free signals providing diagno...a's advanced microcircuit technology provides for ...allowing for the creation of a high-density digita...
Vironostika® HTLV-I/II
... assays for the blood screening market. We have re...t funding from the National Heart, Lung, and Blood...cleix WNV Assay. This assay was made available for...l New Drug Application (IND) on July 1, 2003, and ...
...CR) technology, the worlds leading nucleic acid am...of Roches blood screening assays and other diagnos...d unique regions of genetic material to be amplifi... levels) in only a few hours. In addition to its a...
Medicine Products: